Castle Biosciences (CSTL) Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Castle Biosciences in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CSTL shares.
View CSTL analyst ratings or view top-rated stocks.

4 equities research analysts have issued 12-month price targets for Castle Biosciences' stock. Their CSTL share price forecasts range from $25.00 to $54.00. On average, they predict the company's share price to reach $40.57 in the next year. This suggests a possible upside of 237.5% from the stock's current price.
View analysts price targets for CSTL or view top-rated stocks among Wall Street analysts.

Castle Biosciences' stock was trading at $23.54 at the start of the year. Since then, CSTL stock has decreased by 48.9% and is now trading at $12.02.
View the best growth stocks for 2023 here.

Castle Biosciences saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 878,100 shares, a decline of 11.0% from the April 30th total of 986,400 shares. Based on an average daily volume of 145,300 shares, the short-interest ratio is currently 6.0 days.
View Castle Biosciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our CSTL earnings forecast.

Castle Biosciences, Inc. (NASDAQ:CSTL) issued its earnings results on Wednesday, May, 3rd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by $0.30. The business had revenue of $42.04 million for the quarter, compared to the consensus estimate of $37.63 million. Castle Biosciences had a negative trailing twelve-month return on equity of 17.74% and a negative net margin of 47.11%.

ETFs with the largest weight of Castle Biosciences (NASDAQ:CSTL) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), First Trust Innovation Leaders ETF (ILDR), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), iShares Micro-Cap ETF (IWC), iShares U.S. Healthcare Providers ETF (IHF), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB) and ProShares Ultra Nasdaq Biotechnology (BIB).

Castle Biosciences updated its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $170.00 million-$180.00 million, compared to the consensus revenue estimate of $173.41 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Castle Biosciences investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), DexCom (DXCM), QUALCOMM (QCOM), Teladoc Health (TDOC), Applied Materials (AMAT), Incyte (INCY) and Intel (INTC).

(CSTL) raised $50 million in an initial public offering on Thursday, July 25th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. SVB Leerink and Baird served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Castle Biosciences trades on the NASDAQ under the ticker symbol "CSTL."

Castle Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Wasatch Advisors LP (11.16%), BlackRock Inc. (7.94%), Principal Financial Group Inc. (4.82%), Granahan Investment Management LLC (4.50%), Kornitzer Capital Management Inc. KS (2.43%) and Palisade Capital Management LP (2.16%). Insiders that own company stock include Adam Jay Sussman, Bernhard E Spiess, Bernhard E Spiess, Daniel Bradbury, David S Kabakoff, Derek J Maetzold, Derek J Maetzold, Frank Stokes, Jeffrey E Eberwein, Joseph C Cook III, Kristen M Oelschlager, Mara G Aspinall, Tiffany Olson and Tobin W Juvenal.
View institutional ownership trends.

Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CSTL stock can currently be purchased for approximately $12.02.

Castle Biosciences (NASDAQ:CSTL) has a market capitalization of $320.81 million and generates $137.04 million in revenue each year. The company earns $-67,140,000.00 in net income (profit) each year or ($2.71) on an earnings per share basis.

The company employs 342 workers across the globe.

Castle Biosciences' mailing address is 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546. The official website for the company is castlebiosciences.com. The company can be reached via phone at (866) 788-9007 or via email at ir@castlebiosciences.com.